Meanwhile, the S&P BSE Sensex was up 103.39 points, or 0.51%, to 19,774.93.
On BSE, 36,733 shares were traded in the counter as against an average daily volume of 51,452 shares in the past one quarter.
The stock hit a high of Rs 714.80 so far during the day, which is record high for the stock. The stock hit a low of Rs 700 so far during the day. The stock had hit a 52-week low of Rs 507 on 15 June 2012.
The stock had outperformed the market over the past one month till 6 May 2013, rising 13.02% compared with the Sensex's 6.63% rise. The scrip had also outperformed the market in past one quarter, rising 17% as against Sensex's 0.17% rise.
The large-cap pharma firm has an equity capital of Rs 89.53 crore. Face value per share is Rs 2.
Lupin's consolidated net profit jumped 42.6% to Rs 335.23 crore on 37.6% growth in net sales to Rs 2465.87 crore in Q3 December 2012 over Q3 December 2011.
More From This Section
Headquartered in Mumbai, Lupin is a pharmaceutical company producing and developing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB and Cephalosporin segment.
Powered by Capital Market - Live News